Literature DB >> 14582332

Clinical and immunological factors associated with lupus nephritis in patients from northwestern Colombia.

Juan Manuel Anaya1, Mauricio Uribe, Adriana Pérez, Juan F Sánchez, Luis F Pinto, José F Molina, María C Londoño, Martha E Cadavid, Gustavo Matute.   

Abstract

A cross-sectional and multicenter study was undertaken to analyze the clinical and immunological characteristics at diagnosis associated with nephritis in northwestern Colombian patients with systemic lupus erythematosus (SLE). Thirty-nine patients with lupus nephritis were included and were compared to 100 SLE patients without nephritis. A multivariate analysis was performed. The patients who developed nephritis had a higher frequency of oral ulcers (41% vs. 21%, OR = 3.1, 95% CI: 1.3-7.5 p = 0.01) and malar erythema (77% vs. 45%, OR = 4.4, 95% CI: 1.8-10.8 p = 0.001). Lupus nephritis was observed in 77% of cases during the first year of the disease. The frequency of anti-DNA antibodies was higher in patients with nephritis, however, differences were not statistically significant (83% vs 64%, OR = 2.6, 95% CI: 1.03-6.41, p = 0.06). The presence of other autoantibodies (anti-Ro, anti-La, anti-RNP, anti-Sm and anticardiolipin) at diagnosis was similar in both groups. This autoantibody profile remained unchanged throughout the evolution of the disease. Patients with lupus nephritis had a higher prevalence of arterial hypertension (60% vs 10%, OR = 13.7, 95% IC: 5-37, p = 0.00001) and hyperlipidemia (30% vs 7%, OR = 8.1, 95% IC: 2.5-27, p = 0.0006) at onset. Finally, patients with lupus nephritis required more hospitalizations (> 1) over the course of disease (89% vs 60%, OR = 7.8, 95% CI: 2.1-29, p = 0.002). In conclusion, lupus nephritis appears early during the course of SLE. Malar erythema, oral ulcers, hypertension and hyperlipidemia at onset of disease are associated factors. Lupus nephritis is a major risk factor leading to repeated hospitalizations. This study may help to assist in public health policies in our population in order to improve patient outcomes while simultaneously reducing disease costs.

Entities:  

Mesh:

Year:  2003        PMID: 14582332

Source DB:  PubMed          Journal:  Biomedica        ISSN: 0120-4157            Impact factor:   0.935


  3 in total

Review 1.  Lupus nephritis in Colombians: contrasts and comparisons with other populations.

Authors:  Juan-Manuel Anaya; Carlos Cañas; Rubén D Mantilla; Ricardo Pineda-Tamayo; Gabriel J Tobón; Catalina Herrera-Diaz; Diego M Rendón; Adriana Rojas-Villarraga; Mauricio Uribe
Journal:  Clin Rev Allergy Immunol       Date:  2011-06       Impact factor: 8.667

2.  Mestizos with systemic lupus erythematosus develop renal disease early while antimalarials retard its appearance: data from a Latin American cohort.

Authors:  G J Pons-Estel; G S Alarcón; P I Burgos; L Hachuel; G Boggio; D Wojdyla; R Nieto; A Alvarellos; L J Catoggio; M Guibert-Toledano; J Sarano; L Massardo; G M Vásquez; A Iglesias-Gamarra; L T Lavras Costallat; N A Da Silva; J L Alfaro; I Abadi; M I Segami; G Huerta; M H Cardiel; B A Pons-Estel
Journal:  Lupus       Date:  2013-07-15       Impact factor: 2.911

3.  Clinical outcomes of kidney transplants on patients with end-stage renal disease secondary to lupus nephritis, polycystic kidney disease and diabetic nephropathy.

Authors:  John Fredy Nieto-Ríos; Lina María Serna-Higuita; Sheila Alexandra Builes-Rodriguez; Ricardo Cesar Restrepo-Correa; Arbey Aristizabal-Alzate; Catalina Ocampo-Kohn; Angélica Serna-Campuzano; Natalia Cardona-Díaz; Nelson Darío Giraldo-Ramirez; Gustavo Adolfo Zuluaga-Valencia
Journal:  Colomb Med (Cali)       Date:  2016-03-30
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.